Assembly Biosciences Inc. (V7B)

Overview

Assembly Biosciences, Inc., established in 2005 and based in South San Francisco, California, is a biopharmaceutical entity focused on the discovery and advancement of therapeutic solutions aimed at combating hepatitis B virus (HBV) infection. Initially known as Ventrus Biosciences, Inc., the company underwent a rebranding to Assembly Biosciences, Inc. in June 2014. Engaged in cutting-edge research, Assembly Biosciences is pioneering the development of next-generation HBV core inhibitors and exploring innovative small molecule therapies not only for HBV but also for hepatitis delta virus (HDV) and herpesvirus. The company's dedication to tackling viral diseases extends through multiple partnerships and collaborations, including agreements with BeiGene, Ltd., Arbutus Biopharma Corporation, Antios Therapeutics, Inc., Indiana University Research and Technology Corporation, and Gilead Sciences, Inc. These strategic alliances are formed to amplify its research capabilities and bolster the development and commercialization of its groundbreaking therapeutic candidates.

Products and Services

• ABI-4334 - A next-generation HBV core inhibitor currently undergoing Phase 1a studies. This candidate represents the company's commitment to developing potent antivirals targeted at HBV infection.
• ABI-H3733 - Another HBV core inhibitor from Assembly's pipeline, ABI-H3733, is in Phase 1b clinical study, indicating a further extension of the company's endeavors in combating HBV through innovative therapies.
• Orally Bioavailable HBV/HDV Entry Inhibitor and Liver-Focused Interferon-a Receptor Agonist - These novel small molecule approaches aim at disrupting the HBV and HDV lifecycle, offering new hope for patients battling these infections.
• Herpesvirus Programs:
  • ABI-5366 HSV-2 - A long-acting helicase inhibitor focused on managing herpes simplex virus type 2 (HSV-2). This program showcases Assembly Biosciences' efforts to extend its antiviral research beyond hepatitis to address other critical viral infections.
  • Pan-Herpes Non-Nucleoside Polymerase Inhibitors - Aimed at treating transplant-associated infections, this development underscores the company's commitment to broadening the scope of its antiviral therapies.
• Collaboration Agreements - These include:
  • A partnership with BeiGene, Ltd. to advance the commercialization of novel core inhibitor product candidates for chronic HBV infection in China and its territories.
  • A clinical trial collaboration with Arbutus Biopharma Corporation for conducting randomized, multi-center, and open-label clinical studies.
  • Agreement with Antios Therapeutics, Inc. focusing on triple combination therapy, further exemplifying Assembly Biosciences' dedication to exploring synergistic treatment modalities.
  • A license agreement with Indiana University Research and Technology Corporation and a partnership with Gilead Sciences, Inc. to foster the development of next-generation therapeutics for serious viral diseases.